Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT00125372
Official study title

Study of Tarceva and Targretin in Stage I-II Lung Cancer

Study summary

The purpose of this study is to learn the effects on lung cancer of 2 new drugs, Tarceva and Targretin, given in combination before surgical removal of the tumor. Tarceva is approved by the Food and Drug Administration (FDA) for lung cancer. Targretin is approved for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiederlotinib (Tarceva) and bexarotene (Targretin)

The study team can explain what participation involves.

Who it may be forEarly-stage or resectable

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jan 8, 2019 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Dartmouth-Hitchcock Medical Center

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Not applicable
Sponsor
Dartmouth-Hitchcock Medical Center
Interventions being studied
Drug: erlotinib (Tarceva) and bexarotene (Targretin)
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Early-stage or resectable→
Treatment approach
Surgery→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Resectable stage I or II non-small-cell lung cancer
  • Prior tissue biopsy (not cytology) available for research analysis
  • Adequate hepatic and renal function
Reasons someone may not be able to joinExclusion criteria

Prior chemotherapy or radiotherapy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Norris Cotton Cancer CenterLebanon, New Hampshire

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 8, 2019. Always confirm current availability with the study team.

View original record ↗